Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPsychiatry/Behavioral HealthAnthem Aristada Initio Prior Auth Coverage | OpenP…
    Ask Trek AI about this page
    ModifiedAnthemPolicy CC-0083

    Aristada Initio (aripiprazole lauroxil) — Medical Necessity and Prior Authorization Criteria

    Customize your policy alerts

    Sign up for Anthem Policy CC-0083 alerts

    Get alerted when Policy CC-0083 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity criteria and coding for Aristada Initio (aripiprazole lauroxil) long-acting injectable for initiation or re-initiation of Aristada therapy in adults with schizophrenia; applies to medical benefit prior authorization determinations.

    Policy Summary
    PayerAnthem
    PolicyAristada Initio (aripiprazole lauroxil) — Medical Necessity and Prior Authorization Criteria
    Policy CodePolicy CC-0083
    Change TypeRevised
    Effective Date03/26/2026
    Last ReviewFeb 20, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document age ≥18, schizophrenia diagnosis, and established tolerability to oral aripiprazole.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+minimum age for coverage
    F20.0-F20.9diagnosis codes referenced

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    J1943HCPCS code
    oral requiredtolerability prerequisite

    Coverage Criteria for Aristada Initio

    Initial Therapy

    Requests may be approved when ALL of the following criteria are met:

    Aristada Initio approval criteria

    • Age: Individual is 18 years of age or older>=18 years
    • Diagnosis: Individual has a diagnosis of schizophreniaICD-10 F20.0-F20.9
    • Oral tolerability: Individual has established tolerability with oral aripiprazoledocumented tolerability

      Required prerequisite

    • Initiation status: Individual is initiating or re-initiating therapy with Aristada
    • Concomitant Aristada injection: Will be used in conjunction with first Aristada (aripiprazole lauroxil) injection (may be same day or up to 10 days later)<=10 days if not same day
    • Oral aripiprazole dose rules: Will be used in conjunction with one 30 mg dose of oral aripiprazole for either: initiating therapy with Aristada OR re-initiating therapy after >7 weeks since last Aristada 441 mg injection or >12 weeks after other Aristada strengths30 mg single oral dose

      Follow specified timing for re-initiation

    Denial triggers (NOT approved)

    • Repeat dosing: Use for repeat Aristada dosing (routine repeat use of Aristada Initio) is not approved
    • Lack of oral tolerability: Individual has not established tolerability to oral aripiprazole

      Requests without documented oral aripiprazole tolerability are not approved

    Requests for Aristada Initio (aripiprazole lauroxil) used as a repeat dose for ongoing Aristada maintenance are not approved. Aristada Initio is intended only to initiate or re-initiate Aristada therapy and is not for routine repeat dosing.

    Requests where the individual has not demonstrated tolerability to oral aripiprazole are not approved. Established tolerability with oral aripiprazole is a required prerequisite for coverage of Aristada Initio.

    Coding and Age Requirements

    HCPCSHCPCSCovered
    J1943Injection, aripiprazole lauroxil, (Aristada Initio), 1 mg
    ICD-10 DiagnosisICD-10
    F20.0-F20.9Schizophrenia
    inv-06: Age — >= 18 years
    Minimum ageIndividual is 18 years of age or older
    Age-based approval threshold>= 18 years
    Population coveredAdults with schizophrenia (age 18+)
    Policy effective age ruleRequests may be approved only if individual meets minimum age of 18 years

    Provider Requirements, Prior Authorization, and Denials

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Requests will be approved when all clinical criteria are met, including: age ≥ 18 years, diagnosis of schizophrenia, established tolerability to oral aripiprazole, and use of Aristada Initio only to initiate or re‑initiate Aristada IM therapy in conjunction with the first Aristada injection and a single 30 mg oral aripiprazole dose.

    • Prior authorization required
    • Approve when ALL clinical criteria are met: age ≥18; diagnosis of schizophrenia; established tolerability to oral aripiprazole; initiating or re‑initiating Aristada in conjunction with first Aristada injection and one 30 mg oral aripiprazole dose
    Step Therapy

    Tolerability and Sequencing Requirements

    Aristada Initio is intended ONLY for initiation or re‑initiation of Aristada IM therapy and not for routine repeat dosing. The individual must have established tolerability to oral aripiprazole prior to use of Aristada Initio. Aristada Initio plus a single 30 mg oral aripiprazole dose allows immediate transition to Aristada without the usual 21‑day oral supplementation. The first Aristada injection may be given the same day as Aristada Initio or up to 10 days afterward.

    Background

    Aristada Initio (aripiprazole lauroxil) is an intramuscular extended‑release injection indicated to initiate or re‑initiate Aristada long‑acting injectable therapy for schizophrenia in adults. It enables initiation or re‑initiation of Aristada without the usual prolonged 21‑day oral supplementation required by other regimens and must be used with a single concomitant 30 mg oral aripiprazole dose per labeling when starting or re‑starting therapy.

    Definitions

    inv-12: Definition — Aristada Initio (IM aripiprazole lauroxil)
    DefinitionIM injection of aripiprazole lauroxil used to initiate or re-initiate Aristada therapy without the need for the usual 21-day oral supplementation
    Concomitant oral dose requirementRequires a single 30 mg oral aripiprazole dose to be given concomitantly per labeling
    Intended useFor initiation or re-initiation of Aristada long-acting injectable therapy in adults with schizophrenia
    Not for repeat dosingNot intended for routine repeat Aristada dosing; use for repeat dosing is not approved

    Long-Acting Injectable Treatment Modalities

    Long-acting injectable antipsychotic (Aristada Initio)

    Modality: Long-acting injectable initiation: Aristada Initio used to initiate or re-initiate Aristada long-acting injectable therapy without the need for the standard 21-day oral supplementation; must be given with a single 30 mg oral aripiprazole dose per labeling

    Intended only for initiation or re-initiation; tolerability to oral aripiprazole required

    Policy Summary
    PayerAnthem
    PolicyAristada Initio (aripiprazole lauroxil) — Medical Necessity and Prior Authorization Criteria
    Policy CodePolicy CC-0083
    Change TypeRevised
    Effective Date03/26/2026
    Last ReviewFeb 20, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document age ≥18, schizophrenia diagnosis, and established tolerability to oral aripiprazole.
    SourceLink
    On This Page
    Coverage Criteria for Aristada InitioCoding and Age RequirementsProvider Requirements, Prior Authorization, and DenialsBackgroundDefinitionsLong-Acting Injectable Treatment Modalities
    • Aristada Initio intended only for initiation or re‑initiation of Aristada IM therapy — not for repeat Aristada dosing
    • Must have established tolerability to oral aripiprazole before initiating Aristada Initio
    • Use Aristada Initio with one 30 mg oral aripiprazole dose; first Aristada injection can be same day or within 10 days
    Billing Rule

    Required Coding on Requests

    Include the HCPCS code J1943 and a supporting diagnosis of schizophrenia when submitting requests for Aristada Initio.

    • HCPCS: J1943 – Injection, aripiprazole lauroxil (Aristada Initio), 1 mg
    • ICD‑10 diagnosis: F20.0–F20.9 (schizophrenia)
    Denial Risk

    Denial Triggers

    Requests may be denied if the member is using Aristada Initio for repeat Aristada dosing or if tolerability to oral aripiprazole has not been established.

    • Do not approve for repeat Aristada dosing
    • Do not approve if oral aripiprazole tolerability not established